← Insights
Weekly digest
Weekly digest, Oct 12 to Oct 18, 2026: 269 new earnings analyses
Published Oct 18, 2026
269 new earnings analyses (including DLTH, DMRC, DMAC) and 5 market briefs from Oct 12 to Oct 18, 2026.
This week: 269 new earnings analyses and 5 market briefs were published from Oct 12 to Oct 18, 2026. Everything below is taken from those pieces; nothing here is new reporting.
New earnings analyses
| Report | Revenue | Revenue vs. a year earlier | Diluted EPS | EPS vs. a year earlier |
|---|---|---|---|---|
| DLTH Q2 2026 | $121M | -7.8% | $0.50 | +1150.0% |
| DMRC Q2 2026 | $7.4M | -7.8% | -$0.54 | -42.1% |
| DMAC Q2 2026 | n/a | n/a | -$0.19 | -5.6% |
| DLPN Q2 2026 | $14M | +2.5% | -$0.13 | 0.0% |
| DLO Q2 2026 | $400M | +55.8% | $0.18 | +28.6% |
| DLHC Q3 2026 | $44M | -46.9% | -$1.16 | n/a |
| DKNG Q2 2026 | $1.4B | -4.6% | -$0.14 | n/a |
| DKI H1 (Interim) 2026 | $5.9M | +13.9% | -$1.51 | n/a |
| DJT Q2 2026 | $1.7M | +89.0% | -$0.86 | n/a |
| DJCO Q3 2026 | $27M | +15.3% | -$7.90 | n/a |
| DIOD Q2 2026 | $446M | +21.7% | $1.00 | +1.0% |
| DIBS Q2 2026 | $23M | +5.3% | -$0.03 | +75.0% |
| DHC Q2 2026 | $365M | -4.5% | -$0.16 | -57.9% |
| DGXX Q2 2026 | $6.6M | -18.3% | -$0.17 | +34.6% |
| DGNX Full Year 2026 | $3.6M | +77.2% | -$1.20 | n/a |
| DGII Q3 2026 | $139M | +29.0% | $0.40 | +48.1% |
| DFSC Q3 2026 | CAD 2.7M | +92.0% | -CAD 1.28 | +65.3% |
| DFTX Q2 2026 | n/a | n/a | -$1.44 | -188.0% |
| DGICA Q2 2026 | $241M | -2.4% | $0.60 | +30.4% |
| DFDV Q2 2026 | $3.3M | +66.9% | -$1.00 | n/a |
| DETX Q2 2026 | $42K | -90.2% | -$0.43 | n/a |
| DERM Q2 2026 | $19M | +23.3% | -$0.01 | n/a |
| DDI Q2 2026 | $94M | +11.2% | $13.27 | +50.5% |
| DCOY Q2 2026 | $230K | n/a | -$4.46 | n/a |
| DCX H1 (Interim) 2026 | $0K | n/a | $3.33 | n/a |
| DBVT Q2 2026 | n/a | n/a | -$0.12 | n/a |
| DCBO Q2 2026 | $69M | +13.0% | $0.08 | -20.0% |
| DCTH Q2 2026 | $29M | +20.6% | $0.07 | 0.0% |
| DBGI Q2 2026 | $1.2M | -46.3% | -$13.59 | +58.0% |
| DBX Q2 2026 | $632M | +0.9% | $0.42 | -6.7% |
| DAVE Q2 2026 | $171M | +29.7% | $0.49 | -21.0% |
| DAKT Full Year 2026 | $839M | +10.9% | $0.92 | n/a |
| CZWI Q2 2026 | $16M | -0.2% | $0.11 | -66.7% |
| DAIO Q2 2026 | $5.1M | -13.4% | -$0.17 | n/a |
| CZNC Q2 2026 | $39M | +34.6% | $0.79 | +97.5% |
| CZFS Q2 2026 | $30M | +8.8% | $2.12 | +20.5% |
| CZR Q2 2026 | $3.0B | +3.0% | -$0.30 | n/a |
| CYTK Q2 2026 | $29M | -57.1% | -$1.50 | -33.9% |
| CYRX Q2 2026 | $49M | +7.7% | -$0.20 | n/a |
| CYPH Q2 2026 | n/a | n/a | $0.18 | n/a |
Biggest swings in revenue
Year-over-year revenue change as reported in each analysis, among this week's reports.
Fastest growth
- NRIX Q3 2026: revenue +8426.3%
- CYN Q2 2026: revenue +328.3%
- CLIR Q2 2026: revenue +321.1%
Slowest growth or decline
- CRIS Q2 2026: revenue -100.0%
- CRVO Q2 2026: revenue -100.0%
- CLDX Q2 2026: revenue -97.0%
What the analyses found
- DLTH Q2 2026 (Revenue $121M (-7.8%) · EPS $0.50 (+1150.0%)): Duluth Trading's Q2 net income jumped to $18.4M from $1.3M, but $16.3M of it was a one-time IEEPA tariff refund; net sales fell 7.8% to $121.4M as online sales dropped 11.5%.
- DMRC Q2 2026 (Revenue $7.4M (-7.8%) · EPS -$0.54 (-42.1%)): Digimarc's Q2 2026 revenue fell 8% to $7.4M and its net loss widened to $12.1M on a $5.4M CEO payout charge, while ARR dropped 27% to $11.6M and a going-concern warning preceded an $18.2M share sale.
- DMAC Q2 2026 (EPS -$0.19 (-5.6%)): DiaMedica's Q2 2026 net loss widened to $10.1M as R&D rose 40% on its stroke trial and FDA-requested animal studies; $43.5M in cash must stretch to a ReMEDy2 interim look now expected in Q1 2027.
- DLPN Q2 2026 (Revenue $14M (+2.5%) · EPS -$0.13 (0.0%)): Dolphin Entertainment grew Q2 2026 revenue 2.5% to $14.4M, but payroll and Socialyte litigation costs widened the operating loss to $1.0M and the net loss to $1.6M, with $24.8M of debt against $7.7M of cash.
- DLO Q2 2026 (Revenue $400M (+55.8%) · EPS $0.18 (+28.6%)): dLocal payment volume rose 92% to US$17.7B and net income 28% to US$54.8M, but a falling take rate and 46% opex growth held operating profit to +15%; TPV and gross profit guidance raised.
- DLHC Q3 2026 (Revenue $44M (-46.9%) · EPS -$1.16): DLH revenue fell 46.9% to $44.2M as legacy contracts moved to small-business set-asides and the VA pharmacy work ended; a $10.4M tax write-off drove a $16.8M net loss while $128.7M of floating-rate debt looms.
- DKNG Q2 2026 (Revenue $1.4B (-4.6%) · EPS -$0.14): DraftKings' betting volume rose 14.5% to $13.1B in Q2 2026, but bettor-friendly results and heavier promotions cut its sports margin to 6.8%, so revenue fell 4.6% to $1.44B and it posted a $67.6M net loss while keeping full-year guidance.
- DKI H1 (Interim) 2026 (Revenue $5.9M (+13.9%) · EPS -$1.51): DarkIris grew first-half FY2026 revenue 13.9% to $5.93M on more paying players and higher spend per payer, but $2.13M of expensed game-enhancement costs and new marketing turned a $0.91M profit into a $1.90M loss, with cash down to $0.47M and a going-concern warning ahead of heavily dilutive raises.
- DJT Q2 2026 (Revenue $1.7M (+89.0%) · EPS -$0.86): Trump Media lost $238.1 million in Q2 2026, about 79% of it from falling bitcoin, Cronos and crypto-linked securities values, while revenue rose 89% to just $1.67 million.
- DJCO Q3 2026 (Revenue $27M (+15.3%) · EPS -$7.90): Daily Journal posted a $10.9M net loss in fiscal Q3 2026 as its six-stock portfolio fell $24.1M on paper, while revenue rose 15.3% and operating income jumped 63% on Journal Technologies software growth.
- DIOD Q2 2026 (Revenue $446M (+21.7%) · EPS $1.00 (+1.0%)): Diodes' Q2 2026 revenue rose 21.7% to $445.5M on AI-server and automotive demand, operating income tripled and adjusted EPS doubled to $0.70, though GAAP EPS was flat at $1.00 after a gain-heavy year-ago quarter; Q3 guidance calls for ~$510M revenue and a 35% gross margin.
- DIBS Q2 2026 (Revenue $23M (+5.3%) · EPS -$0.03 (+75.0%)): 1stDibs cut its Q2 2026 net loss to $1.0M from $4.3M on 5% revenue growth to $23.3M, mostly by trimming marketing, while GMV rose 7% on bigger orders as Active Buyers fell 10%.
Plus 257 more on the latest reports page.
Market briefs this week
- Regional banks and Travelers post Q3 results – Market Brief, Oct 16, 2026: Travelers, M&T, Regions and Truist filed quarterly results with the SEC as September CPI came in at +0.6% and the Fed stayed quiet.
- TSMC record profit, BofA fine, Morgan Stanley beat – Market Brief, Oct 15, 2026: TSMC reports record quarterly profit as Bank of America falls on a $1.2 billion Treasury fine and Morgan Stanley beats on trading revenue.
- BofA fined $1.2B; BlackRock assets near $15.5T – Market Brief, Oct 14, 2026: Bank of America's profit fell after a $1.2 billion Treasury penalty, BlackRock's assets reached nearly $15.5 trillion, and Morgan Stanley reported results.
- UnitedHealth lifts outlook; Visa wins China nod – Market Brief, Oct 13, 2026: UnitedHealth reported Q3 results and raised its outlook, Visa won Chinese approval for bank card clearing, and Emerson filed quarterly results.
- Banks kick off earnings; Fed weighs inflation – Market Brief, Oct 12, 2026: Big banks start earnings season Tuesday, this week's inflation data may shape the Fed's late-October decision, and Goldman Sachs turns more positive on stocks.
Assembled automatically each week from this site's own published analyses and briefs. Figures are as stated in each linked report. For information only; not investment advice.
Related analyses
- Duluth Holdings Inc. (DLTH) · Q2 2026Revenue $121M (-7.8%) · EPS $0.50 (+1150.0%)
Duluth Trading's Q2 net income jumped to $18.4M from $1.3M, but $16.3M of it was a one-time IEEPA tariff refund; net sales fell 7.8% to $121.4M as online sales dropped 11.5%.
- Digimarc Corporation (DMRC) · Q2 2026Revenue $7.4M (-7.8%) · EPS -$0.54 (-42.1%)
Digimarc's Q2 2026 revenue fell 8% to $7.4M and its net loss widened to $12.1M on a $5.4M CEO payout charge, while ARR dropped 27% to $11.6M and a going-concern warning preceded an $18.2M share sale.
- DiaMedica Therapeutics Inc. (DMAC) · Q2 2026EPS -$0.19 (-5.6%)
DiaMedica's Q2 2026 net loss widened to $10.1M as R&D rose 40% on its stroke trial and FDA-requested animal studies; $43.5M in cash must stretch to a ReMEDy2 interim look now expected in Q1 2027.
- Dolphin Entertainment, Inc. (DLPN) · Q2 2026Revenue $14M (+2.5%) · EPS -$0.13 (0.0%)
Dolphin Entertainment grew Q2 2026 revenue 2.5% to $14.4M, but payroll and Socialyte litigation costs widened the operating loss to $1.0M and the net loss to $1.6M, with $24.8M of debt against $7.7M of cash.
For information only; not investment advice.